| Sep 15, 2026 | CJS Securities | Robert Labick | Downgrade | Market Outperform→Market Perform | — |
| Sep 14, 2026 | Citigroup | Ronald Josey | PT Raise | Neutral | $9→$11 |
| Sep 11, 2026 | Barrington Research | Gary Prestopino | Downgrade | Outperform→Underperform | — |
| Sep 11, 2026 | Needham | Chris Pierce | Downgrade | Buy→Hold | — |
| Aug 17, 2026 | Citigroup | Ronald Josey | PT Raise | Neutral | $7→$9 |
| Aug 11, 2026 | Barclays | John Babcock | Downgrade | Equal-Weight→Underweight | $8→$6 |
| Jul 22, 2026 | Barclays | John Babcock | PT Raise | Equal-Weight | $7→$8 |
| Jun 1, 2026 | Barrington Research | Gary Prestopino | Downgrade | Outperform→Market Perform | $7 |
| Mar 2, 2026 | Barclays | John Babcock | PT Cut | Equal-Weight | $8→$7 |
| Feb 25, 2026 | Goldman Sachs | Eric Sheridan | PT Cut | Buy | $13→$10 |
| Feb 24, 2026 | Barrington Research | Gary Prestopino | Upgrade | Market Perform→Outperform | — |
| Feb 24, 2026 | Citigroup | Ronald Josey | Downgrade | Buy→Neutral | $13→$7 |
| Feb 24, 2026 | B. Riley Securities | Naved Khan | PT Cut | Buy | $17→$16 |
| Feb 24, 2026 | Needham | Chris Pierce | Maintained | Buy | $9 |
| Jan 21, 2026 | Barclays | John Babcock | PT Raise | Equal-Weight | $7→$8 |
| Dec 11, 2025 | Jefferies | John Colantuoni | Downgrade | Buy→Hold | $9 |
| Dec 4, 2025 | Barclays | John Babcock | PT Raise | Equal-Weight | $6→$7 |
| Nov 21, 2025 | Citigroup | Ronald Josey | PT Cut | Buy | $17→$13 |
| Nov 12, 2025 | Barclays | John Babcock | Initiate | Equal-Weight | $6 |
| Nov 7, 2025 | Goldman Sachs | Eric Sheridan | PT Cut | Buy | $21→$13 |
